Anthem Biosciences block deal: ₹1,275 crore stake sale

Deal in focus: institutions buy 3.05% via block trades

Global investors led by Societe Generale, Prudential Hong Kong and Ghisallo Capital Management acquired a combined stake of about 3% in Anthem Biosciences through open market transactions. The purchase was executed as a block deal, according to data available on the National Stock Exchange (NSE). In total, investors bought 1,71,14,604 shares, representing a 3.05% stake in the company. The average purchase price was ₹744.80 per share, taking the aggregate transaction value to ₹1,274.69 crore (reported broadly as ₹1,275 crore). The seller was promoter Aruna Ganesh, who offloaded an equal number of shares and exited the company. Anthem Biosciences is described as a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO) providing research, development and manufacturing services to global pharmaceutical firms.

Who bought the shares: foreign and domestic institutions

The buyer list included a mix of foreign investors and Indian institutions. Besides Societe Generale, Prudential Hong Kong and Ghisallo Capital Management, other foreign participants in the transaction were Luxembourg-based Nordea Asset Management, Integrated Core Strategies Asia Pte Ltd and Social Protection Fund. On the domestic side, multiple mutual funds participated, including SBI Mutual Fund, HDFC Mutual Fund, Kotak Mahindra Mutual Fund, UTI Mutual Fund, Edelweiss Mutual Fund, Canara Robeco Mutual Fund, 360 ONE Mutual Fund, Mahindra Manulife Mutual Fund and WhiteOak Capital Mutual Fund. The block also saw buying from PI Opportunities AIF V LLP (an affiliate of Premji Invest). Indian insurers named in the deal included Kotak Mahindra Life Insurance Company, Bajaj Life Insurance, and ICICI Prudential Life Insurance. The spread across global and domestic pools of capital indicates the stake was placed with diversified institutional demand.

Seller and promoter holding: Aruna Ganesh exits

The shares were sold by promoter Aruna Ganesh, who exited the company after the transaction. Following the sale, the combined holding of promoters and promoter group entities in Anthem Biosciences declined to 71.63% from 74.68%. The change reflects dilution of the promoter group’s stake through a secondary transaction rather than any issuance of new shares. The trade therefore reshaped ownership on the margin while leaving the company’s capital structure unchanged. The deal size and the breadth of buyers made it one of the more closely watched trades in the counter. Market participants generally track such trades for signals on liquidity, free float, and institutional positioning.

What is a block deal, and what it means operationally

A block deal is a large, pre-arranged transaction executed on the exchange, typically between a selling shareholder and institutional buyers. In this case, the transaction involved a promoter selling shares to institutions, with no new shares being created. As a result, the company’s operations are not directly affected by the transaction itself. The reported floor price for the trade was ₹715 per share, around 7% below the previous day’s closing price, based on the information provided. Such pricing is common in large secondary placements, where sellers may offer a discount to clear size in one go. The key operational takeaway remains that the transaction was a transfer of ownership in existing shares.

Stock reaction: early surge, then steadier trade

The stock’s price action reflected active trading around the deal. Shares of Anthem Biosciences surged to a day high of ₹811 on NSE on 18 June after the block deal worth nearly ₹1,275 crore was executed in the pre-market window. The stock was reported to be up by about 5% as the news moved through the market, and at 10:07 am it was trading up 3.80% at ₹796.65. Separately, post-transaction trading was also described as flat at ₹798.25 apiece on the NSE. A quoted price for 18 June 2026 was ₹798.10, reflecting intraday volatility around the event. These datapoints together show a sharp initial reaction followed by more stable trading near the ₹798 level.

Dividend and other corporate datapoints

On corporate actions, Anthem Biosciences announced a dividend of ₹2 per share with an ex-date of 25 June 2026. Such announcements can influence short-term trading behavior, particularly for investors tracking dividend eligibility dates. The stock has gained nearly 25% so far this year, as per the information provided. Its 52-week high was reported at ₹873.50 and the 52-week low at ₹579.15. These figures provide context on where the stock is trading relative to its recent range.

Snapshot: key numbers from the transaction and market data

Valuation and classification details cited for the stock

Additional market statistics cited for Anthem Biosciences include a market capitalisation of ₹43,225.22 crore as of 18 June 2026. The stock was placed in the Health Care sector and Biotechnology sub-sector. The P/E (price-to-earnings) ratio was cited at 73.04, while the P/B (price-to-book) ratio was cited at 17.94. These valuation metrics are often referenced by investors assessing whether a stock’s price reflects its earnings and book value. They are also useful for comparing the company against peers in pharma services and related life sciences segments. However, the block deal itself primarily changes who owns shares, not the company’s underlying earnings.

Why the deal matters for investors tracking CRDMO plays

Anthem Biosciences operates as a CRDMO, offering integrated drug discovery, development and manufacturing services, including work across proteins, antibodies, peptides and highly potent compounds, as described in the provided details. For investors, the presence of multiple global and domestic institutional buyers in a single trade is notable because it can broaden institutional ownership and potentially improve market liquidity. The promoter group’s holding reduction from 74.68% to 71.63% also increases non-promoter shareholding marginally. At the same time, the trade was structured as an exchange transaction, keeping the company’s operations unaffected. The next near-term corporate marker on the calendar, based on available information, is the dividend ex-date of 25 June 2026.